| Description |
1 online resource |
| Series |
Hematologic malignancies |
|
Hematologic malignancies (Series)
|
| Contents |
Intro; Contents; Part I: Diagnostics and Prognosis; 1: Morphology and Flow Cytometry; 1.1 MDS Nomenclature: WHO2016; 1.2 Peripheral Blood; 1.3 Bone Marrow; 1.3.1 Counting Blasts; 1.3.2 Features of Dysplasia; 1.3.3 Iron Staining; 1.4 Special Subtypes of MDS; 1.4.1 Hypoplastic MDS and MDS with Myelofibrosis; 1.4.2 ICUS and IDUS; 1.5 Flow Cytometry; References; 2: Diagnosis and Prognosis: Molecular; 2.1 Introduction; 2.2 Cytogenetics; 2.2.1 Recurrent Cytogenetic Abnormalities; 2.2.1.1 Chromosome 5q Deletions; 2.2.1.2 Chromosome 7 Abnormalities; 2.2.2 Clinical Implications |
|
2.2.2.1 Diagnosis and Classification2.2.2.2 Clinical Features: Genotype Phenotype Correlation; 2.2.2.3 Prognosis; 2.2.2.4 Therapeutic Implications; 2.3 Gene Mutations; 2.3.1 Recurrent Mutated Pathways; 2.3.1.1 Epigenetic Regulators: DNA Methylation and Histone Modification; 2.3.1.2 Splicing Factors; 2.3.1.3 Transcriptional Regulators, Signal Transducers and Tyrosine Kinases; 2.3.1.4 TP53 Alterations; 2.3.1.5 Cohesin Complex; 2.3.2 Clinical Implications; 2.3.2.1 Diagnosis and Classification; 2.3.2.2 Clinical Features Genotype- Phenotype Correlation; 2.3.2.3 Prognosis |
|
2.3.2.4 Therapeutic Implications: Novel Targeted Therapy and Predictors of Response2.4 Gene Expression Profiling; References; 3: Histology; 3.1 Immunohistochemistry; 3.2 Hypoplastic MDS; 3.3 MDS with Bone Marrow Fibrosis (MDSf); References; 4: Cytogenetics of MDS; 4.1 Introduction; 4.2 Chromosome Banding Analysis; 4.3 Fluorescence InSitu Hybridization; 4.4 Value of FISH inMDS withaNormal Karyotype or Insufficient Metaphase Yield; 4.5 FISH-Analysis of Peripheral Blood; 4.6 CD34+ FISH of Peripheral Blood; 4.6.1 Background; 4.6.2 Method; 4.6.3 CD34+FISH-Trial |
|
4.6.4 Clonal Evolution by FISH4.6.5 Conclusions fortheApplication ofpb FISH inMDS; 4.7 Complex Abnormalities and Karyotype Evolution; 4.8 Clinical Scores: Scoring-ƯSystems with Cytogenetic Components inMDS; References; 5: Chronic Myelomonocytic Leukemia (CMML); 5.1 Introduction; 5.2 CMML Diagnostic; 5.2.1 WHO 2016 Diagnostic Criteria; 5.2.2 Peripheral Blood Cells; 5.2.3 Immunophenotyping of Blood Monocytes; 5.2.4 Bone Marrow Examination; 5.2.5 Cytogenetic Abnormalities; 5.2.6 Molecular Analyses; 5.3 CMML Clinical Heterogeneity; 5.3.1 Common Presentation |
|
5.3.2 Therapy-Related CMML5.3.3 Autoimmune and Inflammatory Diseases; 5.3.4 Eosinophilic Tissue Infiltration; 5.3.5 Second Primary Malignancy; 5.3.6 AML Transformation; 5.3.7 Associated Plasmacytoid Dendritic Cell Neoplasm; 5.3.8 Associated Systemic Mastocytosis; 5.3.9 Associated Histiocytic Disorder; 5.4 CMML Pathophysiology; 5.4.1 The Cell of Origin; 5.4.2 Growth Factor Hypersensitivity; 5.4.3 The Role of Epigenetic Alterations; 5.4.4 Intrinsic Defects inMonocyte Properties; 5.4.5 The Suspected Role oftheMicroenvironment; 5.4.6 CMML Risk Stratification |
| Summary |
This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection |
| Notes |
Online resource; title from PDF title page (SpringerLink, viewed June 13, 2018) |
| Subject |
Myelodysplastic syndromes -- Diagnosis
|
|
Myelodysplastic syndromes -- Treatment
|
|
Myelodysplastic Syndromes
|
|
Oncology.
|
|
Haematology.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Hematology
|
|
Medicine
|
|
Oncology
|
| Form |
Electronic book
|
| Author |
Platzbecker, Uwe, editor
|
|
Fenaux, Pierre, editor.
|
| ISBN |
9783319768793 |
|
3319768794 |
|
3319768786 |
|
9783319768786 |
|
